<DOC>
	<DOC>NCT00779506</DOC>
	<brief_summary>This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients. The eligible patient will be assigned to study treatment with Quetiapine XR on Day 1. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Documented clinical diagnosis meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSMIV) criteria PANSS total score of at least 70 at enrolment and at assignment Day 1 CGI Severity of Illness score of at least 4 (moderately ill) at enrolment and at assignment Day 1 and with worsening of the patient's condition during the 3 weeks Known intolerance or lack of response to quetiapine fumarate Administration of a depot antipsychotic injection within one dosing interval (for the depot) before assignment Substance or alcohol dependence at enrolment Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSMIV criteria within 4 weeks prior to enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Acute schizophrenia</keyword>
	<keyword>PANSS</keyword>
</DOC>